Jacob Ledesma, MD
Internal Medicine · Rumford, MENPI 1497753271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Pfizer at 27.3% of the total. Among internal medicine clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $13.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$150
- GSK$79
- Lilly USA, LLC$64
- Boehringer Ingelheim$61
- AstraZeneca$57
- Amgen$41
- plus $98 from 5 others
What the payments were for
- Food & beverage$551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $150 |
| GSK | 5 | $79 |
| Lilly USA, LLC | 4 | $64 |
| Boehringer Ingelheim | 3 | $61 |
| AstraZeneca | 4 | $57 |
| Amgen | 2 | $41 |
| Novartis | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Novo Nordisk | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Merck | 1 | $11 |
How this compares
$551 in reported general payments places this provider in the 90th percentile of 445 internal medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 15 | $146 |
| Cefdinir | 17 | $141 |
| Prednisone | 26 | $80 |
| Rosuvastatin Calcium | 13 | $64 |
| Lisinopril | 18 | $64 |
| Oxycodone Hcl | 12 | $49 |
| Furosemide | 12 | $37 |
| Azithromycin | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rumford
- Thomas DelucaRumford$1K
- Nananda ColPortland$124K
- Heidi DeblockPortland$27K
- Gene ChengAugusta$22K
- Elizabeth DennisWestbrook$17K
- Hassan AbouleishHoulton$15K
- Peter GuzzettiAugusta$11K
- Linford StillsonWestbrook$11K
- Peter LeightonBridgton$10K
- Tony VargheseBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.